Trials / Unknown
UnknownNCT04927039
Effects of Iloprost on Oxygenation During One-lung Ventilation in Supine-positioned Patients
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Yonsei University · Academic / Other
- Sex
- All
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
One-lung ventilation (OLV) is essential during mediastinal mass excision. However, OLV induces a drastic increase of intrapulmonary shunt due to maintained pulmonary perfusion through the nonventilated lung. In addition, it is reported that supine positioning of patient during OLV, which is required during mediastinal mass excision, results in worse oxygenation than lateral decubitus positioning. Iloprost is a prostaglandin analogue and when inhaled during OLV, it acts selectively on the pulmonary vasculature, reducing pulmonary vascular resistance of well-ventilated lung and thereby alleviating ventilation-perfusion mismatch. The purpose of this study is to evaluate the effects of inhaled iloprost on oxygenation during one-lung ventilation in patients undergoing mediastinal mass excision.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 5ml of inhaled normal saline | After the initiation of OLV, 5ml of normal saline is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation. |
| DRUG | 20μg (2ml) of inhaled iloprost (Ventavis®) and 3ml of inhaled normal saline | After the initiation of OLV, mixture of iloprost 2ml and normal saline 3ml is inhaled for 20 minutes using ultrasonic nebulizer, which is connected to the inspiratory limb of the ventilator system. Arterial blood gas analysis is performed 20 minutes after the completion of drug inhalation. |
Timeline
- Start date
- 2021-06-24
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2021-06-15
- Last updated
- 2021-06-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04927039. Inclusion in this directory is not an endorsement.